Dr. Madhulika Jupelli received her PhD in cellular immunology from the University of Texas, San Antonio, and did her post-doctoral training at Cedars Sinai Medical Center and at the Los Angeles Children’s Hospital in infectious diseases. Following this, Dr. Jupelli’s industry career led her to several medium- and large- biopharmaceutical companies, including her work at Bristol Myers Squibb, and more recently at Pfizer. Dr. Jupelli has to her name three FDA clinical trials, including a Phase III clinical trial for GBT021601 (Osivelotor) for the treatment of Sickle cell disease. 

E-mail: madhulika.jupelli@asdrp.org